Buprenorphine for Probationers and Parolees
common.study.values.description
“Buprenorphine for Probationers and Parolees: Bridging the Gap Into Treatment”
This five-year study will evaluate the effectiveness of the administration of buprenorphine bridge treatment (BBT) to probationers and parolees compared to treatment as usual (TAU), which consists of referral to a community buprenorphine treatment program.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-yes
common.study.methods.is-healthy-no
Drug - Buprenorphine/Naloxone
Participants will begin buprenorphine pharmacotherapy using the MedicaSafe buprenorphine dispensing device immediately after an on-site intake at a community supervision office and continue such treatment until they are transitioned to community buprenorphine treatment
Treatment as usual
Participants will receive a referral to buprenorphine treatment in the community
participant.views.study.view.additional
participant.views.study.view.scientific-title
Buprenorphine for Probationers and Parolees: Bridging the Gap Into Treatment
common.study.values.clinical-trial-id
NCT03616236
participant.views.study.view.id
en5ZWd
